Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRB037
MIFTS: 67

Cerebral Palsy

Categories: Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Cerebral Palsy

About this section

MalaCards integrated aliases for Cerebral Palsy:

Name: Cerebral Palsy 12 74 20 53 29 54 6 42 3 15 37 17 71 32
Infantile Cerebral Palsy 12 71
Cerebral Palsy, Mixed 71
Mixed Cerebral Palsy 20
Palsy, Cerebral 39
Palsy Cerebral 74

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1969
MeSH 44 D002547
NCIt 50 C34460
SNOMED-CT 67 155024003
ICD10 32 G80 G80.9
UMLS 71 C0007789 C0392549 C0751024
Sources

Summaries for Cerebral Palsy

About this section
MedlinePlus : 42 What is cerebral palsy (CP)? Cerebral palsy (CP) is a group of disorders that cause problems with movement, balance, and posture. CP affects the cerebral motor cortex. This is the part of the brain that directs muscle movement. In fact, the first part of the name, cerebral, means having to do with the brain. The second part, palsy, means weakness or problems with using the muscles. What are the types of cerebral palsy (CP)? There are different types of CP: Spastic cerebral palsy, which is the most common type. It causes increased muscle tone, stiff muscles, and awkward movements. Sometimes it only affects one part of the body. In other cases, it can affect both arms and legs, the trunk, and the face. Dyskinetic cerebral palsy, which causes problems controlling the movement of the hands, arms, feet, and legs. This can make it hard to sit and walk. Ataxic cerebral palsy, which causes problems with balance and coordination Mixed cerebral palsy, which means that you have symptoms of more than one type What causes cerebral palsy (CP)? CP is caused by abnormal development or damage to the developing brain. It could happen when The cerebral motor cortex doesn't develop normally during fetal growth There is an injury to the brain before, during, or after birth Both the brain damage and the disabilities it causes are permanent. Who is at risk for cerebral palsy (CP)? CP is more common among boys than girls. It affects black children more often than white children. Certain medical conditions or events that can happen during pregnancy and delivery that may increase a baby's risk of being born with cerebral palsy, including Being born too small Being born too early Being born a twin or other multiple birth Being conceived by in vitro fertilization (IVF) or other assisted reproductive technology (ART) Having a mother who had an infection during pregnancy Having a mother with certain health problems in pregnancy, such as thyroid problems Severe jaundice Having complications during birth Rh incompatibility Seizures Exposure to toxins What are the signs of cerebral palsy (CP)? There are many different types and levels of disability with CP. So the signs can be different in each child. The signs usually appear in the early months of life. But sometimes there is a delay in getting a diagnosis until after age two. Infants with CP often have developmental delays. They are slow to reach developmental milestones such as learning to roll over, sit, crawl, or walk. They may also have abnormal muscle tone. They may seem floppy, or they may be stiff or rigid. It's important to know that children without CP can also have these signs. Contact your child's health care provider know if your child has any of these signs, so you can get a correct diagnosis. How is cerebral palsy (CP) diagnosed? Diagnosing CP involves several steps: Developmental monitoring (or surveillance) means tracking a child's growth and development over time. If there are any concerns about your child's development, then he or she should have a developmental screening test as soon as possible. Developmental screening involves a giving your child a short test to check for motor, movement, or other developmental delays. If the screenings are not normal, the provider will recommend some evaluations. Developmental and medical evaluations are done to diagnose which disorder your child has. The provider many use many tools to make the diagnosis: A check of your child's motor skills, muscle tone, reflexes, and posture A medical history Lab tests, genetic tests, and/or imaging tests What are the treatments for cerebral palsy (CP)? There is no cure for CP, but treatment can improve the lives of those who have it. It is important to begin a treatment program as early as possible. A team of health professionals will work with you and your child to develop a treatment plan. Common treatments include Medicines Surgery Assistive devices Physical, occupational, recreational, and speech therapy Can cerebral palsy (CP) be prevented? You cannot prevent the genetic problems that can cause CP. But it may be possible to manage or avoid some of the risk factors for CP. For example, making sure that pregnant women have been vaccinated could prevent certain infections that can cause CP in unborn babies. Using cars seats for infants and toddlers could prevent head injuries, which can be a cause of CP. Centers for Disease Control and Prevention

MalaCards based summary : Cerebral Palsy, also known as infantile cerebral palsy, is related to spastic diplegia and spastic cerebral palsy, and has symptoms including seizures, tremor and back pain. An important gene associated with Cerebral Palsy is ADD3 (Adducin 3), and among its related pathways/superpathways are Clathrin derived vesicle budding and Lysosome. The drugs Levodopa and Topiramate have been mentioned in the context of this disorder. Affiliated tissues include Blood and Umbilical Cord, and related phenotypes are growth/size/body region and behavior/neurological

Disease Ontology : 12 A brain disease that is caused by damage to the motor control centers of the developing brain during pregnancy, during childbirth or after birth, which affects muscle movement and balance.

GARD : 20 Cerebral palsy refers to a group of neurological disorders that can affect the brain and/or spinal cord. Signs and symptoms generally appear during infancy or early childhood and vary based on the type of cerebral palsy (spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy), the severity of the condition and which area(s) of the brain are affected. Common features include a lack of muscle coordination when performing voluntary movements (ataxia); stiff or tight muscles and exaggerated reflexes (spasticity); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a "scissored" gait; and muscle tone that is either too stiff or too floppy. Cerebral palsy is caused by abnormal brain development or damage to the developing brain. Most of these problems occur as the baby grows in the womb; however, they can happen at any time during the first 2 years of life. There is no cure for cerebral palsy, but treatment is available to alleviate some symptoms. This may include physical, occupational, and speech therapy; certain medications; surgery; and/or devices (i.e. braces, wheelchairs) to aid in mobility.

CDC : 3 Cerebral palsy (CP) is a group of disorders that affect a person's ability to move and maintain balance and posture. CP is the most common motor disability in childhood. CDC estimates that an average of 1 in 323 children in the U.S. have CP.

NINDS : 53 The term cerebral palsy refers to a group of neurological disorders that appear in infancy or early childhood and permanently affect body movement, muscle coordination, and balance. CP affects the part of the brain that controls muscle movements.  The majority of children with cerebral palsy are born with it, although it may not be detected until months or years later. The early signs of cerebral palsy usually appear before a child reaches 3 years of age. The most common are a lack of muscle coordination when performing voluntary movements (ataxia); stiff or tight muscles and exaggerated reflexes (spasticity); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a “scissored” gait; and muscle tone that is either too stiff or too floppy. Other neurological symptoms that commonly occur in individuals with CP include seizures, hearing loss and impaired vision, bladder and bowel control issues, and pain and abnormal sensations. A small number of children have CP as the result of brain damage in the first few months or years of life, brain infections such as bacterial meningitis or viral encephalitis, or head injury from a motor vehicle accident, a fall, or child abuse. The disorder isn't progressive, meaning that the brain damage typically doesn't get worse over time. Risk factors associated with CP do not cause the disorder but can increase a child's chance of being born with the disorder.CP is not hereditary.

Wikipedia : 74 Cerebral palsy (CP) is a group of permanent movement disorders that appear in early childhood. Signs and... more...

Sources

Related Diseases for Cerebral Palsy

About this section

Diseases related to Cerebral Palsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 933)
# Related Disease Score Top Affiliating Genes
1 spastic diplegia 33.6 AP4S1 AP4M1 AP4E1 AP4B1
2 spastic cerebral palsy 33.5 PLP1 KANK1 GAD1 AP4S1 AP4E1 AP4B1
3 spastic paraplegia 52, autosomal recessive 33.0 AP4S1 AP4M1 AP4E1 AP4B1
4 spastic paraplegia 47, autosomal recessive 33.0 AP4S1 AP4M1 AP4E1 AP4B1
5 inherited congenital spastic tetraplegia 32.9 KANK1 GAD1 ADD3
6 spastic paraplegia 50, autosomal recessive 32.9 AP4S1 AP4M1 AP4E1 AP4B1
7 hereditary spastic paraplegia 51 32.8 AP4S1 AP4M1 AP4E1 AP4B1
8 spastic paraplegia 2, x-linked 32.6 PLP1 AP4M1 AP4B1
9 neonatal jaundice 32.5 TNF IL6 IL1B
10 quadriplegia 32.5 PLP1 KANK1 AP4S1 AP4M1 AP4E1 AP4B1
11 hereditary spastic paraplegia 32.3 TUBB4A PLP1 GAD1 AP4S1 AP4M1 AP4E1
12 asphyxia neonatorum 31.9 IL6 IL1B BDNF
13 chorioamnionitis 31.7 TNF MMP8 IL6 IL1B
14 brain injury 31.7 IL6 IL1B BDNF
15 paraplegia 31.7 PLP1 AP4S1 AP4M1 AP4E1 AP4B1
16 sleep disorder 31.5 TNF IL6 IL1B BDNF
17 spinal cord injury 31.5 TNF IL6 BDNF
18 traumatic brain injury 31.4 IL6 IL1B BDNF
19 back pain 31.3 IL6 IL1B
20 encephalomalacia 31.3 TNF IL6 IL1B BDNF
21 acute cystitis 31.2 TNF IL6 IL1B
22 pain agnosia 31.2 TNF IL6 IL1B BDNF
23 gingivitis 31.2 TNF MMP8 IL6 IL1B
24 rubella 31.2 TNF IL6 IL1B
25 preterm premature rupture of the membranes 31.1 TNF MMP8 IL6 IL1B
26 sleep apnea 31.1 TNF IL6 IL1B BDNF
27 speech and communication disorders 31.1 TNF IL6 IL1B BDNF
28 bone resorption disease 31.1 TNF IL6 IL1B
29 funisitis 31.0 TNF MMP8 IL6 IL1B
30 exudative vitreoretinopathy 1 31.0 TNF IL6 IL1B BDNF
31 periodontitis 31.0 TNF MMP8 IL6 IL1B
32 bacterial vaginosis 30.9 TNF MMP8 IL6 IL1B
33 placenta disease 30.9 TNF IL6 IL1B
34 esophagitis 30.9 TNF IL6 IL1B
35 decubitus ulcer 30.9 TNF IL6 IL1B
36 toxoplasmosis 30.9 TNF IL6 IL1B
37 exanthem 30.8 TNF IL6 IL1B
38 ileus 30.8 TNF IL6 IL1B
39 pneumonia 30.8 TNF MMP8 IL6 IL1B
40 tendinitis 30.8 TNF IL6 IL1B
41 osteomyelitis 30.8 TNF IL6 IL1B
42 ap-4-associated hereditary spastic paraplegia 30.8 AP4S1 AP4M1 AP4E1 AP4B1
43 perinatal necrotizing enterocolitis 30.7 TNF IL6 IL1B
44 anxiety 30.7 TNF MPP5 IL6 IL1B GAD1 BDNF
45 alacrima, achalasia, and mental retardation syndrome 30.7 SMARCA4 PMM2 MPP5 BRCA2 AP4S1 AP4M1
46 central nervous system disease 30.7 TNF PLP1 IL6 IL1B BDNF
47 pyelonephritis 30.7 TNF IL6 IL1B
48 pulmonary disease, chronic obstructive 30.7 TNF MMP8 IL6 IL1B
49 gingival overgrowth 30.7 TNF MMP8 IL6
50 purpura 30.7 TNF IL6 IL1B

Comorbidity relations with Cerebral Palsy via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Cerebral Palsy:



Diseases related to Cerebral Palsy
Sources

Symptoms & Phenotypes for Cerebral Palsy

About this section

UMLS symptoms related to Cerebral Palsy:


seizures, tremor, back pain, abnormality of extrapyramidal motor function, involuntary movements, dystonia, headache, torticollis, syncope, athetosis, pain, myokymia, muscle fibrillation, chronic pain, sciatica, asterixis, vertigo/dizziness, sleeplessness, muscle rigidity

MGI Mouse Phenotypes related to Cerebral Palsy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.17 AP4E1 AP4M1 BDNF BRCA2 CC2D1A GAD1
2 behavior/neurological MP:0005386 10.15 AP4B1 AP4E1 BDNF BRCA2 CC2D1A GAD1
3 nervous system MP:0003631 10.1 AP4B1 AP4E1 BDNF BRCA2 CC2D1A GAD1
4 respiratory system MP:0005388 9.76 AP4E1 BDNF CC2D1A GAD1 IL6 PMM2
5 skeleton MP:0005390 9.65 AP4E1 AP4M1 BRCA2 GAD1 IL1B IL6
6 vision/eye MP:0005391 9.28 AP4E1 BDNF IL6 KANK1 MPP5 PLP1
Sources

Drugs & Therapeutics for Cerebral Palsy

About this section

Drugs for Cerebral Palsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 178)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levodopa Approved Phase 4 59-92-7 6047
2
Topiramate Approved Phase 4 97240-79-4 5284627
3
Trihexyphenidyl Approved Phase 4 144-11-6, 58947-95-8 5572
4
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
5
Amitriptyline Approved Phase 4 50-48-6 2160
6
Perphenazine Approved Phase 4 58-39-9 4748
7
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
8
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
9
Tetrabenazine Approved, Investigational Phase 4 58-46-8 6018
10
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
11
Amantadine Approved Phase 4 768-94-5 2130
12
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
13
Racepinephrine Approved Phase 4 329-65-7 838
14
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
15
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
16
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
17
Acetaminophen Approved Phase 4 103-90-2 1983
18
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
19
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
20
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
21
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
22 Dihydroxyphenylalanine Phase 4
23 Carbidopa, levodopa drug combination Phase 4
24 Anticonvulsants Phase 4
25 Hypoglycemic Agents Phase 4
26 Calcium, Dietary Phase 4
27 Muscarinic Antagonists Phase 4
28 Cholinergic Antagonists Phase 4
29 calcium channel blockers Phase 4
30 Acidophilus Phase 4
31 Sunflower Phase 4
32 Sodium Channel Blockers Phase 4
33 Gastrointestinal Agents Phase 4
34 Antidepressive Agents Phase 4
35 GABA Modulators Phase 4
36 Excitatory Amino Acid Antagonists Phase 4
37 Psychotropic Drugs Phase 4
38 Diuretics, Potassium Sparing Phase 4
39 Antipsychotic Agents Phase 4
40 Amitriptyline, perphenazine drug combination Phase 4
41 Anti-Anxiety Agents Phase 4
42 Antidepressive Agents, Tricyclic Phase 4
43 Antiemetics Phase 4
44 Antiparkinson Agents Phase 4
45 Anti-Infective Agents Phase 4
46 Dopamine Agents Phase 4
47 Antiviral Agents Phase 4
48 Respiratory System Agents Phase 4
49 Anti-Asthmatic Agents Phase 4
50 Adrenergic beta-Agonists Phase 4

Interventional clinical trials:

(show top 50) (show all 823)
# Name Status NCT ID Phase Drugs
1 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
2 Effects of Functional Electrical Stimulation on Gait in Children With Hemiplegic and Diplegic Cerebral Palsy Unknown status NCT02462018 Phase 4
3 Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy Unknown status NCT02244515 Phase 4 dexmedetomidine
4 Effect of Erythropoietin on Preterm Brain Injury Completed NCT02036073 Phase 4 recombinant human erythropoietin
5 Recurrent Crying Spells in Cerebral Palsy With Spastic Quadriparesis - A Crossover Study Completed NCT01955655 Phase 4 Baclofen
6 Efficacy of the Supplementation With a Symbiotic, a Prebiotic and a Probiotic to Produce a Beneficial Effect on the Intestinal Microbiota and on the Characteristics of Feces in Children With Cerebral Palsy (CP) and Chronic Constipation Completed NCT03117322 Phase 4
7 SPREAD AND EFFECTIVENESS OF BOTULINUM NEUROTOXIN A IN SPASTIC EQUINUS IN CEREBRAL PALSY:SHORT-TERM STUDY Completed NCT01276015 Phase 4 Botulinum Toxin Type A
8 A Randomized Controlled Trial on Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy Completed NCT00432055 Phase 4 Botulinum toxin type A (Botox);placebo (saline)
9 Alterations of Functional Activities and Leg Stiffness After Hamstring Lengthening in Cerebral Palsy Children Completed NCT00154830 Phase 4
10 A Placebo Controlled, Cross-over, Double Blind, Randomized, Clinical Trial to Compare the Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy Completed NCT01860196 Phase 4 Meditoxin;Normal saline
11 Management of Excessive Crying in Cerebral Palsy -A Placebo-controlled, Fixed-sequence, Crossover Clinical Trial. Completed NCT04523935 Phase 4 Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.
12 Multi-center, Single Arm, Open-label, Phase IV Clinical Trial to Evaluate the Safety and Efficacy of MEDITOXIN® in Children With Cerebral Palsy Completed NCT01256021 Phase 4 Botulinum Toxin Type A
13 Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies. A Prospective, Randomized and Double-blinded Study Completed NCT00964639 Phase 4 Ropivacaine;Saline
14 Use of Amantadine in Treating Cognitive and Motor Impairments in Adolescents and Adults With Cerebral Palsy Recruiting NCT04273737 Phase 4 Amantadine Hydrochloride
15 Efficacy of a Peri-Operative Surgical-Site, Multimodal Drug Injection in Pediatric Patients With Cerebral Palsy Undergoing Hip Surgery: A Randomized Controlled Trial Recruiting NCT04074265 Phase 4 Ropivacaine injection;normal saline
16 Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Recruiting NCT02546999 Phase 4 botox;placebo
17 Pharmacokinetics and Safety of Treatment With Paracetamol in Children and Adults With Spinal Muscular Atrophy and Cerebral Palsy Recruiting NCT03648658 Phase 4 Paracetamol 120Mg/5mL Oral Suspension
18 Intrathecal (IT) Baclofen Drug Distribution Pilot Study Active, not recruiting NCT02903823 Phase 4 Baclofen bolus injection
19 A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging Active, not recruiting NCT02633241 Phase 4 Dexmedetomidine-Propofol
20 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Terminated NCT00752934 Phase 4 oral baclofen + placebo;placebo + oral baclofen
21 Improvement After Botulinum Toxin A Injections to the Upper Extremities in Children With Cerebral Palsy Terminated NCT00549471 Phase 4
22 Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy Withdrawn NCT01386255 Phase 4 Baclofen;placebo
23 Phase 2/3 Application of Botulinum Neurotoxin Type A in Salivary Glands as a Treatment of Chronic Drooling in Patients With Cerebral Palsy: A Controlled Clinical Trial. Unknown status NCT01489904 Phase 2, Phase 3
24 Targeted Hip Progressive Resistance Training to Improve Single Leg Balance and Walking in Children With Cerebral Palsy Unknown status NCT01633736 Phase 3
25 Modulation of Brain Plasticity After Perinatal Stroke: The PLASTIC CHAMPS Trial Unknown status NCT01189058 Phase 2, Phase 3
26 Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below Years. It is Self Funded (Patients' Own Funding) Clinical Trial Unknown status NCT01832454 Phase 2, Phase 3
27 Project:Intensive Habilitation (PIH) -a New Norwegian Multidisciplinary Program for Intensive Training for Children With Disabilities Unknown status NCT00202761 Phase 2, Phase 3
28 Magnesium Prevention of Brain Injury in Preterm Infants Unknown status NCT00065949 Phase 3 magnesium sulfate
29 Effect of Early Application of Recombinant Human Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome Unknown status NCT03110341 Phase 3 Erythropoietin;Normal saline
30 A Randomized Controlled Trial on Integrated Management of Pronation Deformity of Children With Cerebral Palsy Treated by Botulinum Toxin-A Completed NCT03472261 Phase 3 Botulinum toxin type A
31 Effectiveness of Intermittent Serial Casting on Spastic Wrist Flexion Deformity in Children With Cerebral Palsy Treated By Botulinum Toxin A Completed NCT03306212 Phase 3 Botulinum toxin A
32 Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Children With Cerebral Paralysis Completed NCT01929434 Phase 3
33 Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy: A Double-Blind, Randomized, Placebo-Controlled Trial Completed NCT00261131 Phase 3 Botulinum Toxin A
34 Integrated Management With Brain Stimulation and Hybrid Training Enhances Functional Gains in Children With Cerebral Palsy Treated by Botulinum Toxin A Completed NCT03302871 Phase 3 Botulinum toxin type A
35 Is it Possible to Improve Static and Dynamic Postural Stability in Cerebral Palsy Children by Modulating Attention? Completed NCT01799304 Phase 3
36 Evaluation of the Efficacy of "MEOPA" Used to Obtain Better ROM Immediately After Multilevel Surgery in Children With Spastic Diplegia, Quadriplegia or Hemiplegia. Completed NCT00632528 Phase 3 MEOPA;Medicinal air
37 Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy and Death in Preterm Infants (MASP-STUDY) Completed NCT01492608 Phase 3 Magnesium sulphate
38 Double-blinded, Randomized, Active Control Comparative, Multicenter-designed, Phase III Clinical Trial to Evaluate the Safety and Efficacy of "Botulax®" Versus "Botox®" in Children With Cerebral Palsy Completed NCT01787344 Phase 3 Botulinum Toxin Type A(Botox®);Botulinum toxin type A(Botulax®)
39 A Phase III, Prospective, Multicentre, Open Label, Extension Study Assessing the Long Term Safety and Efficacy of Repeated Treatment With DYSPORT® Used in the Treatment of Lower Limb Spasticity in Children With Dynamic Equinus Foot Deformity Due to Cerebral Palsy Completed NCT01251380 Phase 3
40 Intrathecal Baclofen. Evaluation of a Therapy for Refractory Spasticity in Children With Cerebral Palsy Completed NCT00367068 Phase 3 baclofen, intrathecal
41 Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM) Completed NCT00014989 Phase 3 magnesium sulfate
42 A Phase III, Multicentre, Double Blind, Prospective, Randomised, Placebo Controlled Study Assessing the Efficacy and Safety of DYSPORT® Used in the Treatment of Lower Limb Spasticity in Children With Dynamic Equinus Foot Deformity Due to Cerebral Palsy Completed NCT01249417 Phase 3 Placebo
43 Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy Completed NCT02002884 Phase 3 IncobotulinumtoxinA (8 Units per kg body weight);IncobotulinumtoxinA (6 Units per kg body weight);IncobotulinumtoxinA (2 Units per kg body weight)
44 Post-operative Pain in Children With Cerebral Palsy Following Major Hip Surgery: a Double Blind Randomised Placebo Controlled Trial of Pre-operative Botulinum Toxin Type A Completed NCT01437644 Phase 3 botulinum toxin intramuscular injection
45 Botulinum Toxin Efficiency on Spasticity of Rectus Femoris and Semitendinosus Muscles as Functional Agonist and Antagonist Muscles. Assessment of Efficiency of Botulinum Toxin on Spasticity in Agonist and Antagonist Muscles Using Clinical Assessment and Gait Analysis in Cerebral Palsy Children: Rectus Femoris and Semitendinosus Completed NCT00133861 Phase 2, Phase 3 Botulinum toxin
46 Relationship of Orthotics to Activity and Participation in Children With Cerebral Palsy Completed NCT01527162 Phase 3
47 Open-label, Non-controlled, Multicenter Long-term Study to Investigate the Safety and Efficacy of Xeomin® (Incobotulinumtoxin A, NT 201) for the Treatment of Spasticity of the Lower Limb(s) or of Combined Spasticity of Upper and Lower Limb in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy Completed NCT01905683 Phase 3 IncobotulinumtoxinA (16-20 Units per kg body weight)
48 The Efficacy, Safety and Tolerability of Sativex as an Adjunctive Treatment to Existing Anti-spasticity Medications in Children Aged 8 to 18 Years With Spasticity Due to Cerebral Palsy or Traumatic Central Nervous System Injury Who Have Not Responded Adequately to Their Existing Anti-spasticity Medications: a Parallel Group Randomised, Double-blind, Placebo-controlled Study Followed by a 24-week Open Label Extension Phase Completed NCT01898520 Phase 3 Sativex;Placebo
49 Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy Completed NCT01893411 Phase 3 IncobotulinumtoxinA (16 Units per kg body weight);IncobotulinumtoxinA (12 Units per kg body weight);IncobotulinumtoxinA (4 Units per kg body weight)
50 Individualized Neurodevelopmental Treatment Completed NCT00922077 Phase 3

Search NIH Clinical Center for Cerebral Palsy

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Baclofen
Dantrolene
Dantrolene Sodium

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Cerebral Palsy cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Cerebral Palsy:
Bone marrow-derived mononuclear cells for the treatment of cerebral palsy
Umbilical cord-derived mesenchymal stem cells for treatment of cerebral palsy
Embryonic/Adult Cultured Cells Related to Cerebral Palsy:
Umbilical cord-derived mesenchymal stem cells (family)
Sources

Genetic Tests for Cerebral Palsy

About this section

Genetic tests related to Cerebral Palsy:

# Genetic test Affiliating Genes
1 Cerebral Palsy 29
Sources

Anatomical Context for Cerebral Palsy

About this section

MalaCards organs/tissues related to Cerebral Palsy:

40
Brain, Bone, Cortex, Spinal Cord, Bone Marrow, Eye, Fetal Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cerebral Palsy:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
2 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
Sources

Publications for Cerebral Palsy

About this section

Articles related to Cerebral Palsy:

(show top 50) (show all 22562)
# Title Authors PMID Year
1
A comparison of conventional and minimally invasive multilevel surgery for children with diplegic cerebral palsy. 61 42
33380192 2021
2
Remodelling of femoral head deformity after hip reconstructive surgery in patients with cerebral palsy. 61 42
33380203 2021
3
Slackline Training in Children with Spastic Cerebral Palsy: A Randomized Clinical Trial. 42 61
33233328 2020
4
Identification of proteolipid protein 1 gene duplication by multiplex ligation-dependent probe amplification: first report of genetically confirmed family of Pelizaeus-Merzbacher disease in Korea. 54 61
18437021 2008
5
Reaching movements in childhood dystonia contain signal-dependent noise. 61 54
15996397 2005
6
The Xq22 inversion breakpoint interrupted a novel Ras-like GTPase gene in a patient with Duchenne muscular dystrophy and profound mental retardation. 61 54
12145744 2002
7
Amniotic fluid matrix metalloproteinase-8 and the development of cerebral palsy. 54 61
12235718 2002
8
Deleterious effects of IL-9-activated mast cells and neuroprotection by antihistamine drugs in the developing mouse brain. 54 61
11477207 2001
9
Progress in clinical trials of stem cell therapy for cerebral palsy. 61
33318421 2021
10
Prevention and treatment of cerebral palsy with cord blood stem cells and cord-derived mesenchymal stem cells. 61
33063719 2021
11
White matter injury in the neonatal hypoxic-ischemic brain and potential therapies targeting microglia. 61
33416205 2021
12
Reliability and Validity of the Trunk Control Measurement Scale Among Children and Adolescents With Cerebral Palsy in Tanzania. 61
33357090 2021
13
Using different definitions affected the reported prevalence of neurodevelopmental impairment in children born very preterm. 61
32640081 2021
14
Intravenous paracetamol for neonates: long-term diseases not escalated during 5 years of follow-up. 61
32943529 2021
15
Comparing short-term outcomes between conus medullaris and cauda equina surgical techniques of selective dorsal rhizotomy. 61
33103255 2021
16
Cerebral palsy with autism and ADHD: time to pay attention. 61
33314032 2021
17
The role of magnesium sulfate (MgSO4) in fetal neuroprotection. 61
31092073 2021
18
Cross-cultural adaptation of the Arabic version of Self-Care Domain of Child Engagement in Daily Life and Ease of Caregiving for Children measures. 61
33486394 2021
19
The future of General Movement Assessment: The role of computer vision and machine learning - A scoping review. 61
33571849 2021
20
Sustained low-dose prophylactic early erythropoietin for improvement of neurological outcomes in preterm infants:A systematic review and meta-analysis. 61
33601694 2021
21
Assessing state level variation in signature authority and cause of death accuracy, 2005-2017. 61
33511026 2021
22
Mobile applications in children with cerebral palsy. 61
29275969 2021
23
Obstetric factors associated with uterine rupture in mothers who deliver infants with cerebral palsy. 61
31032674 2021
24
Validity and reliability of the Turkish versions of Assessment of Children's Hand Skills and Children's Hand-Skills Ability Questionnaire in children with hemiplegic cerebral palsy. 61
33338287 2021
25
'What if it were like this?' Perception of mothers of children with cerebral palsy about the ankle-foot orthosis of their children: A qualitative study. 61
33326118 2021
26
A prospective study on transfer of pronator teres to extensor carpi radialis brevis for forearm and wrist deformity in children with cerebral palsy. 61
32990136 2021
27
Decreasing cerebral palsy prevalence in multiple births in the modern era: a population cohort study of European data. 61
32847831 2021
28
Robotic-assisted locomotor treadmill therapy does not change gait pattern in children with cerebral palsy. 61
33290305 2021
29
A Life Course Perspective on Growing Older With Cerebral Palsy. 61
33213304 2021
30
Measuring skeletal muscle morphology and architecture with imaging modalities in children with cerebral palsy: a scoping review. 61
33107594 2021
31
Interventions and lower-limb macroscopic muscle morphology in children with spastic cerebral palsy: a scoping review. 61
32876960 2021
32
Locomotor and robotic assistive gait training for children with cerebral palsy. 61
33225442 2021
33
Benefits of robotic gait rehabilitation in cerebral palsy: lessons to be learned. 61
33354780 2021
34
Vitamin D and iron deficiencies in children and adolescents with cerebral palsy. 61
29342407 2021
35
Development of a new comorbidity index for adults with cerebral palsy and comparative assessment with common comorbidity indices. 61
33289071 2021
36
Better Together: the Australasian Academy of Cerebral Palsy and Developmental Medicine champions equity. 61
33249564 2021
37
Serum trace element and amino acid profile in children with cerebral palsy. 61
33249374 2021
38
Autism and attention-deficit/hyperactivity disorder in children with cerebral palsy: high prevalence rates in a population-based study. 61
33206380 2021
39
Dynamic and Static Stability in Para-Athletes with Cerebral Palsy Considering their Impairment Profile. 61
33599066 2021
40
High-Dose Prednisolone for Treatment of Infantile Spasms After Presumed Perinatal Stroke. 61
33538457 2021
41
Puberty and menarche in young females with cerebral palsy and intellectual disability: a qualitative study of caregivers' experiences. 61
33010048 2021
42
Partnering clinician- and parent-led organizations for guidance on puberty and menarche in cerebral palsy and intellectual disability. 61
33169373 2021
43
Molecular Diagnostic Yield of Exome Sequencing in Patients With Cerebral Palsy. 61
33528536 2021
44
The impact of disease and sociodemographic background on children suffering from cerebral palsy 61
33582650 2021
45
Validity of Parent Ratings of Speech Intelligibility for Children with Cerebral Palsy. 61
33100123 2021
46
Philanthropic funding in cerebral palsy research: translating new knowledge into improved quality of life. 61
33393701 2021
47
CORR Insights®: How Do Complications Within the First 30 Days after Spinal Deformity Surgery in Children with Cerebral Palsy Affect Length of Stay? 61
32511142 2021
48
First-trimester maternal serum biomarkers and the risk of cerebral palsy. 61
33206412 2021
49
Leisure-time physical activity interventions for children and adults with cerebral palsy: a scoping review. 61
33241561 2021
50
A Retrospective Cohort Study on Mortality and Neurodevelopmental Outcomes of Preterm Very Low Birth Weight Infants Born to Mothers with Hypertensive Disorders of Pregnancy. 61
33535243 2021
Sources

Variations for Cerebral Palsy

About this section

ClinVar genetic disease variations for Cerebral Palsy:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MPP5 NM_022474.4(MPP5):c.1289A>G (p.Glu430Gly) SNV Pathogenic 983221 14:67783612-67783612 14:67316895-67316895
2 PMM2 NM_000303.3(PMM2):c.338C>T (p.Pro113Leu) SNV Pathogenic 7723 rs80338700 16:8900255-8900255 16:8806398-8806398
3 PMM2 NM_000303.3(PMM2):c.422G>A (p.Arg141His) SNV Pathogenic 7706 rs28936415 16:8905010-8905010 16:8811153-8811153
4 ADD3 NM_016824.5(ADD3):c.1100G>A (p.Gly367Asp) SNV Pathogenic 242273 rs564185858 10:111882007-111882007 10:110122249-110122249
5 SMARCA4 NM_003072.5(SMARCA4):c.3355C>T (p.Arg1119Cys) SNV Pathogenic 816866 19:11138599-11138599 19:11027923-11027923
6 CC2D1A NC_000019.10:g.13912730_13922079del Deletion Likely pathogenic 812928 19:14023543-14032892
7 TUBB4A NM_006087.4(TUBB4A):c.763G>A (p.Val255Ile) SNV Likely pathogenic 217025 rs767399782 19:6495747-6495747 19:6495736-6495736
8 BRCA2 NM_000059.3(BRCA2):c.8487+3A>G SNV Likely pathogenic 52603 rs81002806 13:32944697-32944697 13:32370560-32370560
Sources

Expression for Cerebral Palsy

About this section
Search GEO for disease gene expression data for Cerebral Palsy.
Sources

Pathways for Cerebral Palsy

About this section

Pathways related to Cerebral Palsy according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Clathrin derived vesicle budding 65
Show member pathways
 12.26 AP4S1 AP4M1 AP4E1 AP4B1
2
Lysosome 36
11.78 AP4S1 AP4M1 AP4E1 AP4B1
3
Rheumatoid arthritis 36
11.74 TNF IL6 IL1B
4
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.66 SMARCA4 GAD1 BDNF
5
Spinal Cord Injury 1
11.64 TNF IL6 IL1B BDNF
6
Th1 Differentiation Pathway 64
Show member pathways
 11.62 TNF IL6 IL1B
7
Pertussis 36
11.61 TNF IL6 IL1B
8
Dendritic Cells Developmental Lineage Pathway 64
11.59 TNF IL6 IL1B
9
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.51 TNF IL6 IL1B
10
Lung fibrosis 1
11.5 TNF IL6 IL1B
11
Legionellosis 36
11.44 TNF IL6 IL1B
12
Malaria 36
11.37 TNF IL6 IL1B
13
Interleukin-10 signaling 65
11.34 TNF IL6 IL1B
14
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.31 TNF PLP1 IL6 IL1B CC2D1A BDNF
15
Transcription_Role of VDR in regulation of genes involved in osteoporosis 23
11.29 TNF IL6 IL1B
16
African trypanosomiasis 36
11.18 TNF IL6 IL1B
17
IL-10 Pathway 63
11.12 TNF IL6 IL1B
18
Development and heterogeneity of the ILC family 1
11 TNF IL6 IL1B
19
Antifolate resistance 36
10.82 TNF IL6 IL1B
20
IL-9 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types 64
10.67 IL6 IL1B
21
Cytokines and Inflammatory Response 1
10.59 TNF IL6 IL1B
Sources

GO Terms for Cerebral Palsy

About this section

Cellular components related to Cerebral Palsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 trans-Golgi network membrane GO:0032588 9.46 AP4S1 AP4M1 AP4E1 AP4B1
2 clathrin adaptor complex GO:0030131 9.26 AP4M1 AP4B1
3 endosome lumen GO:0031904 9.26 AP4S1 AP4M1 AP4E1 AP4B1
4 AP-4 adaptor complex GO:0030124 8.92 AP4S1 AP4M1 AP4E1 AP4B1

Biological processes related to Cerebral Palsy according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.98 TNF PLP1 MMP8 IL6 IL1B
2 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.78 TNF IL6 BDNF
3 positive regulation of JNK cascade GO:0046330 9.77 TNF MMP8 IL1B
4 regulation of insulin secretion GO:0050796 9.74 TNF IL6 IL1B
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.73 TNF SMARCA4 IL6 IL1B
6 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.72 TNF MMP8 IL1B
7 positive regulation of interleukin-8 production GO:0032757 9.71 TNF IL6 IL1B
8 positive regulation of nitric oxide biosynthetic process GO:0045429 9.69 TNF MMP8 IL1B
9 positive regulation of interleukin-6 production GO:0032755 9.67 TNF MMP8 IL6 IL1B
10 protein localization GO:0008104 9.62 AP4S1 AP4M1 AP4E1 AP4B1
11 regulation of neuroinflammatory response GO:0150077 9.59 MMP8 IL6
12 regulation of establishment of endothelial barrier GO:1903140 9.58 TNF IL1B
13 negative regulation of neurogenesis GO:0050768 9.58 TNF IL6 IL1B
14 negative regulation of lipid storage GO:0010888 9.56 TNF IL6
15 positive regulation of fever generation GO:0031622 9.52 TNF IL1B
16 regulation of microglial cell activation GO:1903978 9.49 MMP8 IL6
17 sequestering of triglyceride GO:0030730 9.48 TNF IL1B
18 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.46 TNF IL1B
19 protein targeting GO:0006605 9.46 AP4S1 AP4M1 AP4E1 AP4B1
20 positive regulation of glial cell proliferation GO:0060252 9.43 TNF IL6 IL1B
21 vascular endothelial growth factor production GO:0010573 9.13 TNF IL6 IL1B
22 positive regulation of neuroinflammatory response GO:0150078 8.92 TNF MMP8 IL6 IL1B
Sources

Sources for Cerebral Palsy

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....